Search
GenSci140 for injection, an independently developed targeted folate receptor α subtype dual-epitope antibody-drug conjugate by Jinsai Pharmaceutical—a subsidiary of Changchun High & New Technology—is specifically designed for the treatment of advanced solid tumors. Recently, the National Medical Products Administration issued a 'Notice of Acceptance' for the registration clinical trial application of this drug. This acceptance marks a significant step forward for Jinsai Pharmaceutical, enabling it to expand its business scope, refine its product structure, and enrich and enhance its product line layout in key strategic areas. As a result, it will bolster the company's overall competitiveness. However, given the lengthy and multi-stage process involved in drug development, from research to production, the clinical trial progress of GenSci140 remains subject to uncertainties.
-
C114 Communication Network -
Communication Home
